LLY Stock Discussion (ELI LILLY & Co)

Lilly reports 79% response rate in early ovarian-cancer combination study

Eli Lilly ($LLY) reported the first platinum-sensitive ovarian-cancer results for its investigational antibody-drug conjugate sofetabart mipitecan, given with bevacizumab. In a Phase 1 cohort of 33 women, 23 of the 29 patients with measurable disease had confirmed responses, a 79.3% rate. Six responses were complete. Participants had received a median of three previous systemic regimens, and two-thirds had prior PARP-inhibitor exposure. The findings support Lilly’s ongoing Phase 3 FRAmework-01 p

LLY

@tickerstat12 days ago

Lilly starts construction of $5 billion Virginia cancer-medicine plant

Eli Lilly ($LLY) broke ground on its previously announced $5 billion manufacturing facility in Goochland County, near Richmond, Virginia. The site is intended to produce antibody-drug conjugates and other advanced medicines, and would be Lilly's first facility integrating active-ingredient production with finished-medicine manufacturing. The project is expected to support approximately 650 permanent jobs and 1,800 construction positions. Lilly also committed $40 million to a workforce-developmen

LLY

@tickerstat1 month ago

Lilly’s obesity combination improves weight loss but raises discontinuation rates

Lilly ($LLY) reported that its experimental EloraTZP combination produced average weight loss of up to 23.3% over 48 weeks in a 367-person study involving overweight or obese adults with type 2 diabetes. The highest-dose combination of eloralintide and tirzepatide also reduced A1C by 2.9 percentage points, compared with 14.8% weight loss and a 2.4-point A1C reduction for tirzepatide 15 mg alone. The findings support a planned move into Phase 3 and could broaden Lilly’s metabolic-disease pipeline

LLY

@tickerstat1 month ago

Lilly seeks eczema label update after hand-and-foot study meets endpoints

Lilly ($LLY) said EBGLYSS achieved clear or almost clear hands and feet in 53% of treated patients after 16 weeks, compared with 27% on placebo, in the randomized ADtouch study. The 221-patient trial included adults and adolescents with moderate-to-severe hand-and-foot atopic dermatitis. A substantial improvement in itch occurred in 57% of eligible treated participants versus 19% receiving placebo. Lilly has submitted the results to the FDA for a possible label update and plans additional regula

LLY

@tickerstat1 month ago

Lilly wins US approval for once-weekly insulin Onswik

Eli Lilly ($LLY) received FDA approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, used alongside diet and exercise. The decision gives the company a less frequently administered alternative to daily basal insulin. Lilly expects its prefilled pen to become available in the coming months, with the weekly schedule potentially eliminating more than 300 injections a year. Approval was supported by four Phase 3 QWINT trials involving more than 3,400 adults. The studies